Hongqi Pharmaceutical
HONGQI PHARMACEUTICAL
Cherish life, pay attention to health.
CHERISH LIFE CARE ABOUT HEALTH
Three anti-tuberculosis drugs in Liaoning Province were evaluated by consistency of generic drugs
Category:
Trade info
Author:
Source:
Add time:2019-05-08 15:52
Summary:Liaoning Daily News reporter Zhao Ming reported that on April 14, the reporter learned from the Provincial Food and Drug Administration that following the first declaration of pyrazinamide tablets produced by Shenyang Hongqi Pharmaceutical Co., Ltd.
Liaoning Daily News reporter Zhao Ming reported that on April 14, the reporter learned from the Provincial Food and Drug Administration that following the first declaration of pyrazinamide tablets produced by Shenyang Hongqi Pharmaceutical Co., Ltd. at the beginning of this year and passing the consistency evaluation of generic drugs, The company's rifampicin capsules and isoniazid tablets once again passed the consistency evaluation of generic drugs and obtained approval from the State Food and Drug Administration.
The consistency evaluation of generic drugs refers to the quality consistency evaluation of the generic drugs that have been approved for marketing according to the principle of consistency with the quality and efficacy of the original drugs. The quality and efficacy of the generic drugs are required to meet the original drugs through the evaluation. Consistent level. my country is the hardest hit area of the pulmonary tuberculosis epidemic. Pyrazinamide tablets, rifampicin capsules and isoniazid tablets as urgently needed anti-tuberculosis drugs with significant curative effects are widely used clinically.
Shenyang Hongqi Pharmaceutical Co., Ltd. is the country's largest anti-tuberculosis drug research and development and production base. This time, a total of 4 approval numbers for 3 varieties have passed the generic drug consistency evaluation, marking that the domestic anti-tuberculosis generic drug R&D and production have been compared with foreign original drugs Standing on the same level will provide patients with more choices.
